Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "biopharma"

762 News Found

Thermo Fisher opens Bioprocess Design Center in Hyderabad
Biopharma | December 09, 2025

Thermo Fisher opens Bioprocess Design Center in Hyderabad

Expands bioprocessing footprint across Asia


WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre
R&D | December 09, 2025

WuXi Biologics teams up with Qatar Free Zones Authority to launch first Middle East CRDMO Centre

This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region


Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
Clinical Trials | December 09, 2025

Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial

The study met its primary endpoint and all 11 secondary efficacy endpoints


Halozyme wins German injunction blocking Merck’s Keytruda distribution
Biopharma | December 08, 2025

Halozyme wins German injunction blocking Merck’s Keytruda distribution

While Merck can appeal, Halozyme said it expects the order to hold


Praxis Precision hits milestone in fight against rare paediatric seizures
Clinical Trials | December 08, 2025

Praxis Precision hits milestone in fight against rare paediatric seizures

The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies


Paradigm Health to acquire Flatiron’s clinical research business
News | December 07, 2025

Paradigm Health to acquire Flatiron’s clinical research business

It's an acquisition that aims at forming one of the US's largest oncology trial networks


Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment
Clinical Trials | December 07, 2025

Debiopharm launches pivotal phase III trial for novel quarterly acromegaly treatment

Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development


Biocon to merge Biocon Biologics in $5.5 billion deal
News | December 07, 2025

Biocon to merge Biocon Biologics in $5.5 billion deal

Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million


Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma
Drug Approval | December 06, 2025

Bristol Myers Squibb secures FDA nod for Breyanzi in marginal zone lymphoma

The one-time CAR T cell infusion now becomes the first and only therapy of its kind cleared for this patient population